Anand Subramony Eli Lilly & Company

Anand Subramony is Vice President within the DDCS (Delivery, Device, and Connected Solutions) group at Eli Lilly and he provides leadership to early development of device combination products and novel drug delivery technologies. Prior to joining Lilly, Anand was Vice President within the Biologics Engineering and Targeted Delivery group, at AstraZeneca where he led various cross-functional teams and initiatives in the areas of nanomedicine -drug conjugates, and drug delivery of new modalities including implantable cell therapy devices. He also provided leadership to external innovation and CoSolve, an open innovation platform. Prior to that role Anand headed the Drug Delivery & Device Development at MedImmune/AZ and built an internal team that focused on combination product development, connected devices, digital biomarkers/sensors, as well as advanced novel delivery technologies including oral peptide delivery and other novel controlled release technologies. In other roles, Anand was Principal Fellow and Head of Novel Delivery Technologies at Novartis (NIBR, Cambridge, MA), head of the Materials Science group (E-TRANS) at Alza /J&J (Mountain View, CA), and Director of Materials Science & Drug delivery at Dr. Reddy’s Laboratories (Bridgewater, NJ). With his broad experience in pharma biotech, Anand brings innovation and scientific rigor coupled with execution excellence and sense of urgency to create patient centric products. He has established and managed high-performing teams in all his roles. Dr. Subramony holds an M.S. degree in Materials Science Engineering (IIT, Bombay) and a Ph.D. degree from Purdue University. With several refereed publications and patents, he is a sought-after Key Opinion Leader in the areas of drug delivery and product development.